叶娜 - 苏州大学 - 医学部药学院

个人简介

2016.9–至今：苏州大学药学院，特聘副教授，独立PI 2013.6–2016.8：美国德州大学医学分部，博士后 2008.09-2013.06：中国科学院上海药物研究所，药物化学，理学博士 2004.09-2008.07：沈阳药科大学，国家基础药学理科基地班，理学学士

研究领域

1）靶向神经精神性重大疾病的药物研发 2）抗肿瘤药物的设计与合成 3) 有机方法学在药物研发中的应用

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Mao, Q.; Zhang, B.; Tian, S.; Qin, W.; Chen, J.; Huang, X.-P.; Xin, Y.; Yang, H.; Zhen, X.-C.; Shui, W., Ye, N.* Structural Optimizations and Bioevaluation of N-H Aporphine Analogues as Gq-biased and Selective Serotonin 5-HT2C Receptor Agonists. Bioorg. Chem.2022, 123, 105795. (*通讯作者) Kuang, Y.#; Ye, N.#; Kyani, A.; Ljungman, M.; Paulsen, M.; Chen, H.; Zhou, M.; Wild, C.; Chen, H.; Zhou, J.*; Neamati, N.*. Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer. J. Med. Chem. 2022, 65, DOI: 10.1021/acs.jmedchem.1c02207. (#并列第一作者) Wang, P.;# van der Hoeven, D.;#Ye,N.;# Chen, H.; Liu, Z.; Ma, X.; Montufar-Solis, D.; Rehl, K. M.; Cho, K.-J., Thapa, S.; Chen W., van der Hoeven, R.; Frost, J. A.; Hancock, J. F.;* Zhou, J.* Scaffold Repurposing of Fendiline: Identification of Potent KRAS Plasma Membrane Localization Inhibitors. Eur. J. Med. Chem., 2021, 217, 113381. Ye, N.;* Qin, W.; Tian, S.; Xu, Q.; Wold, E. A.; Zhou, J.; Zhen, X. C. Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases. J. Med. Chem. 2020, 63, 15187-15217. Mao Q, Zhang B, Li W, Tian S, Shui W, Ye, N.* Identification of Novel 1-O-Substituted Aporphine Analogues as Potent 5-HT2C Receptor Agonists. ACS Chem. Neurosci.,2020, 11, 549−559. Mao, Q.; Qin, W.; Zhang, A.; Ye, N.* Overview of Recent Advances on Dopaminergic Strategies for Parkinson’s Disease. Acta Pharmacol. Sin.,2020, 41, 471-482. Xu, Q.; Li B.; Ma, Y.; Sun, F.; Gao, Y.; Ye, N.* K2S2O8-HFIP Synergistic Promoted para-selective sp3 C-H Bond Diarylation of Glycine Esters. Org. Biomol. Chem., 2020, 18, 666-670. Ye, N.* Drug Discovery by Targeting Mutant KRAS. Curr. Top. Med. Chem. 2019, 19, 2079-2080. (Editoral; Guest editor) Ye, N.*; Xu, Q.; Li, W.; Wang, P.; Zhou, J. Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors. Curr. Top. Med. Chem. 2019, 19, 2114-2127. Li, .B.; Mao, Q.; Zhou, J.; Liu, F.; Ye, N.* HFIP-Promoted Michael Reactions: Direct para-Selective C-H Activation of Anilines with Maleimides. Org. Biomol. Chem., 2019, 17, 2242-2246. Ye, N.*; Li, B.; Mao, Q.; Wold, E. A.; Tian, S.; Allen, J. A.; Zhou, J. Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target. ACS Chem. Neurosci.,2019, 10, 190−200. Yuan, B.;#Ye, N.;# Song, S. S.; Wang, Y. T.; Song, Z.; Chen, H. D.; Chen, C. H.; Huan, X. J.; Wang, Y. Q.; Su, Y.; Shen, Y. Y.; Sun, Y. M.; Yang, X. Y.; Chen, Y.; Guo, S. Y.; Gan, Y.; Gao, Z. W.; Chen, X. Y.; Ding, J.; He, J. X.; Zhang, A.;Miao, Z. H.Poly(ADP-ribose)polymerase (PARP) Inhibition and Anticancer Activity of Simmiparib, a New Inhibitor Undergoing Clinical Trials. Cancer Lett., 2017,386, 47-56. Ye, N.; Zhu, Y.; Liu, Z.; Mei, F. C.; Chen, H.; Wang, P.; Cheng, X.; Zhou, J. Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydra- zonoyl cyanide analoguesas potent EPAC antagonists. Eur. J. Med. Chem. 2017,134, 62-71. Ye, N.; Shi, P.-Y.; Zhou, J. Therapetic Potential of Spirooxindoles as Antiviral Agents. ACS Infect. Dis., 2016,2, 382-292. (高被引论文) Ye, N.; Zhu, Y.; Chen, H.; Liu, Z.; Mei, F. C.; Wild, C.; Chen, H.; Cheng, X.; Zhou, J. Structure–Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N’-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists. J. Med. Chem., 2015, 58, 6033-6047. Ye, N.; Ding, Y.; Wild, C.; Shen, Q.; Zhou, J. Small molecule inhibitors targeting activator protein 1 (AP-1). J. Med. Chem.,2014,57, 6930-6948. Ye, N.; Song, Z.; Zhang, A. Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT1A Receptors as New Antipsychotical or Anti-Parkinsonian Agents. Curr. Med. Chem.,2014,21, 437-457. Ye, N.; Neumeyer, J. L.; Baldessarini, R. J.; Zhen, X.; Zhang, A. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders. Chem. Rev.,2013,113, PR123-178. Ye, N.; Chen, C. H.; Chen, T.; Song, Z.; He, J. X.; Huan, X. J.; Song, S. S.; Liu, Q.; Chen, Y.; Ding, J.; Xu, Y.; Miao, Z. H.; Zhang, A. Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors. J. Med. Chem.,2013,56, 2885-2903. Zhang, H.;#Ye, N.;# Zhou, S.; Guo, L.; Zheng, L.; Liu, Z.; Gao, B.; Zhen, X.; Zhang, A. Identification of N-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson’s Agent Possessing a Dopamine D2 and Serotonin 5-HT1A Dual-Agonist Profile. J. Med. Chem.,2011, 54, 4324–4338.